Tanox: Clinical Trials

5 completed, 2 unknown. 3 Phase 4, 2 Phase 1, 2 Phase 2, 1 Phase 3.

By phase and status

Phase	Trials	Status
Phase 4	3	Completed 3
Phase 1	2	Completed 1, Unknown 1
Phase 2	2	Unknown 2
Phase 3	1	Completed 1

Follow Tanox: new trials by email

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
A Study of Efficacy of New Doses of Xolair to Protect From Allergen Challenge in Groups of Asthma Patients Defined by IgE Levels Xolair, Placebo - Asthma	Phase 4	Completed	Novartis	60	2008-02-01	2011-04-19
Open Label Study to Assess Safety and Immunogenicity of Omalizumab Liquid Formulation. omalizumab - Asthma	Phase 3	Completed	Novartis	155	2007-07-01	2011-06-02
Safety and Efficacy Study of TNX-650 to Treat Refractory Hodgkin's Lymphoma TNX-650 - Hodgkin's Lymphoma	Phase 1 / Phase 2	Unknown	Tanox	59	2006-05-01	2008-05-09
Study to Evaluate the Effect of Omalizumab on Improving the Tolerability of Specific Immunotherapy in Patients With Persistent Allergic Asthma Placebo, Omalizumab, Immunotherapy - Allergic Asthma	Phase 4	Completed	Novartis	275	2005-12-01	2016-09-14
Omalizumab in Adult and Adolescent Patients With Severe Persistent Allergic Asthma Omalizumab, Optimized asthma therapy - Asthma	Phase 4	Completed	Novartis	406	2005-11-01	2018-06-29
Effects of TNX-832 (Sunol cH36) in Subjects With Acute Lung Injury/Acute Respiratory Distress Syndrome TNX-832, Placebo - Sepsis, Acute Lung Injury	Phase 1	Completed	Altor BioScience	18	2004-12-01	2025-01-06
TNX-355 With Optimized Background Therapy (OBT) in Treatment-Experienced Subjects With HIV-1 TNX-355 - HIV Infections	Phase 2	Unknown	Tanox	80	2004-03-01	2005-06-24

Conditions studied

Asthma (3)  ·  Acquired Immunodeficiency Syndrome (1)  ·  Acute Lung Injury (1)  ·  Epilepsy, Idiopathic Generalized (1)  ·  HIV Infections (1)  ·  Hodgkin Disease (1)  ·  Lung Diseases (1)  ·  Respiratory Distress Syndrome (1)  ·  Sepsis (1)

Interventions

Omalizumab (4)  ·  ALT-836 (1)  ·  Immunotherapy (1)  ·  ibalizumab (1)  ·  lebrikizumab (1)

Countries

United States (5)  ·  Canada (3)  ·  Germany (3)  ·  Argentina (1)  ·  Belgium (1)  ·  Denmark (1)  ·  Greece (1)  ·  Hungary (1)  ·  Ireland (1)  ·  Israel (1)  ·  Italy (1)  ·  Netherlands (1)  ·  Norway (1)  ·  Poland (1)  ·  Portugal (1)

Top investigators

Anas Younes, MD (1)  ·  Craig Moskowitz, MD (1)  ·  Hing Wong, PhD (1)  ·  Jose Bardelas, MD (1)

Results publications

PMID 21933100, PMID 22340260, PMID 24028677, PMID 33427765